The subscription period in Karolinska Development AB (publ)’s rights issue begins today

Core Viewpoint - Karolinska Development AB is initiating a rights issue to raise approximately SEK 202.6 million for the continued development of existing investments and general corporate purposes [2][6]. Rights Issue Details - The rights issue involves a maximum of 675,193,985 series B shares at a subscription price of SEK 0.30 per share [6]. - The subscription period runs from January 13, 2026, to January 27, 2026, with trading in subscription rights occurring from January 13 to January 22, 2026 [4][6]. - Shareholders holding series A and B shares will have preferential rights to subscribe, with one existing share granting five subscription rights, and two subscription rights allowing the purchase of one new series B share [6]. Financial Commitments - Prior to the rights issue, the company has secured subscription undertakings from its Board of Directors and management amounting to approximately SEK 5.2 million, representing about 2.6% of the rights issue [6]. - Additionally, the company has entered into guarantee commitments totaling approximately SEK 95.2 million, which is about 47% of the rights issue, including the subscription undertakings [6]. Timeline and Trading Information - The estimated date for announcing the outcome of the rights issue is around January 29, 2026, with trading in new shares expected to commence on February 16, 2026 [4][6]. - Trading in paid subscribed shares (BTA) will occur from January 13, 2026, until around February 12, 2026 [4]. Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations [10]. - The company aims to build companies around leading scientists and management teams, co-funded by international investors, to enhance the chances of success in advancing medical innovations [11]. - The company has a portfolio of eleven companies targeting innovative treatments for serious diseases [12].